Application Effect of Levosimendan in Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention
Objective To investigate the application effect of levosimendan in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods A total of 85 AMI patients admitted to Sanmenxia Central Hospital from October 2020 to July 2022 were selected and divided into the levosimendan group(43 cases)and the control group(42 cases)according to the random number table method.The control group was given routine treatment after PCI,and the levosimendan group was given levosimendan on the basis of the control group.The changes of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac troponin Ⅰ(cTnⅠ),brain natriuretic peptide(BNP)]and inflammatory factors indexes[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)]before and 3 days after PCI were compared between the two groups.The patients were followed up for 3 months after PCI,and the incidence of adverse cardiovascular events was compared between the two groups.Results Three days after PCI,the levels of LVEF in the two groups was higher than that before PCI,and LVEF in levosimendan group was higher than that in control group(P＜0.05).The levels of LVEDD,cTnⅠ,BNP,hs-CRP and IL-6 in the two groups were lower than those before PCI,and those in the levosimendan group were lower than those in the control group(P＜0.05).During the 3-month follow-up after PCI,the incidence of adverse cardiovascular events was 4.65％in the levosimendan group,which was lower than 21.43％in the control group(P＜0.05).Conclusion The application of levosimendan in AMI patients after PCI can protect cardiac function,reduce inflammation,and is helpful to prevent the occurrence of adverse cardiovascular events.
万方数据
维普
